scholarly journals MARKETING STUDY OF ORAL FORMS OF OMEPRAZOLE PREPARATIONS USED FOR THE TREATMENT AND PREVENTION OF GASTROESOPHAGEAL REFLUX DISEASE AND GASTRIC ULCER

2021 ◽  
Vol 8 (2) ◽  
pp. 28-37
Author(s):  
L.N. Sheikhmambetova ◽  
E.A. Egorova ◽  
E.Yu. Bekirova ◽  
K.N. Onishchenko
Keyword(s):  
Gastric Ulcer ◽  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Reflux Disease ◽  
The State ◽  
Pharmaceutical Market ◽  
High Price ◽  
Medicinal Products ◽  
Domestic Production ◽  
Trade Names

Some of the most widespread illnesses of alimentary canal are the stomach (gastric) ulcer, duodenal ulcer disease, gastroesophageal reflux diseases. The ethanol of antisecretory treatment of the given acid-dependent diseases are the preparations of the proton pump inhibitor group with omeprazole which is considered to be more effective and investigated. The goal of the research is the oral medications omeprazole (20 mg) assortment market investigation. Materials and methods. The research objects are the State register of medicines data of oral medicinal products including omeprazole dosing 20 mg recorded on the pharmaceutical market as well as the State price register data on the vital medicinal products on April, 4, 2021. Results. According to the SRMP 30 trade names of medicinal products including omeprazole dosing 20 mg as active ingredient in capsules and tablets are registered on the pharmaceutical market in Russian Federation. The omeprazole products distribution in the countries holding registration certificates showed the predominance of domestic production medicinal products (18 trade names, 60 %). The cost analysis of standard daily and course dose oral omeprazole form (20 mg) of different trade names allowed to select economically profitable preparations (”Omeprazole”, LLC “Production of Medicines”, Russia; “Omeprazole”, OJSC ‘‘Synthesis”, Russia; “Omeprazole” LLC BFMP, Russia), the insert of which into the list of medicines to provide the gastroesophageal reflux disease and stomach (gastric) ulcer patients at the regional level is economically feasible as well the medicines with the high price (Losec MUPS AstraZeneca AB, Sweden). Сonclusion. The results of the pharmaceutical market research of oral omeprazole form (20mg) indicates a great majority of generic medicine, a sufficient market capacity, medicine predominance of domestic production (60%).

scholarly journals Gastroesophageal reflux disease after Helicobacter pylori eradication in gastric ulcer patients: A one-year follow-up study

Medicina ◽  
2008 ◽  
Vol 44 (3) ◽  
pp. 211 ◽  
Author(s):  
Laimas Jonaitis ◽  
Gediminas Kiudelis ◽  
Limas Kupčinskas
Keyword(s):  
Helicobacter Pylori ◽  
Gastric Ulcer ◽  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Reflux Disease ◽  
Control Group ◽  
Helicobacter Pylori Eradication ◽  
Group A ◽  
Group B

The aim of this study was to evaluate the course of gastroesophageal reflux disease in gastric ulcer patients after successful Helicobacter pylori eradication (group A), in patients with persistent infection after attempt to eradicate Helicobacter pylori (group B), and in control group without Helicobacter pylori eradication treatment (group C). Materials and methods. Gastric ulcer patients (n=88) were assigned either to the group receiving Helicobacter pylori eradication treatment (54 patients) or to the control group (34 patients; omeprazole treatment for 4 weeks) and were followed up for 1-year or until gastric ulcer relapsed. Gastroesophageal reflux disease was diagnosed in patients who had erosive esophagitis and/or without esophagitis if they experienced heartburn and/or regurgitation at least 2 times a week and it was associated with impairment of daily activities (Genval consensus). Results. The study was completed by 69 patients: 25 in group A, 19 in group B, and 25 in group C. At the beginning and at the end of the follow-up, gastroesophageal reflux disease was diagnosed in 10 (40%) and 9 (36%) group A patients, respectively (P>0.05); in 12 (63%) and 8 (42%) group B patients, respectively (P>0.05); and in 9 (36%) and 5 (20%) group C patients, respectively (P>0.05). At the beginning and at the end of the follow-up, reflux esophagitis was found in 3 (12%) and 5 (20%) group A patients, respectively (P>0.05); in 5 (26%) and 5 (26%) group B patients (P>0.05); in 4 (16%) and 3 (12%) group C patients (P>0.05). Conclusion. There was no statistically significant difference regarding the development of gastroesophageal reflux disease in gastric ulcer patients after Helicobacter pylori eradication, in the patients with persistent infection after attempt to eradicate, and in the control group without Helicobacter pylori eradication treatment.

Association Between Obesity and Gastroesophageal Reflux Disease in SUS Patients in the State of Bahia

2017 ◽  
Vol 112 ◽  
pp. S185-S186
Author(s):  
Amanda Viana ◽  
Bruna Viana ◽  
Leticia Pereira ◽  
Eugenio Viana
Keyword(s):  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Reflux Disease ◽  
The State

scholarly journals Overview of antidepressants on the pharmaceutical market of Ukraine and dynamics of their consumption during 2015-2019

2021 ◽  
pp. 3-13
Author(s):  
Л. В. Яковлєва ◽  
Т. О. Баглай ◽  
О. В. Ткачова ◽  
О. В. Павленко
Keyword(s):  
Government Procurement ◽  
The State ◽  
Pharmaceutical Market ◽  
Outpatient Basis ◽  
Domestic Production ◽  
Abrupt Changes ◽  
Unit Of Measurement ◽  
State And Local ◽  
Trade Names ◽  
Hospital Consumption

Among persistent health and disability disorders in Ukraine, the third place among men and the second among women are neuropsychiatric disorders, in the pharmacotherapy of which antidepressants are widely used. The aim of the work was to study the range and outpatient and hospital consumption of antidepressants in Ukraine. The analysis of the range and volume of antidepressant consumption was conducted in the outpatient market during 2015–2019 and in the hospital market during 2016–2019, according to the analytical company «Proxima Research»/«Morion». Consumption was calculated according to the ATC/DDD methodology. DDD/1 000 inhabitants per day (DID, DDD per 1 000 inhabitants per day) was used as a unit of measurement. The results of the study showed that in the pharmaceutical market of Ukraine during 2015–2019, 94–101 tons of antidepressants were used on an outpatient basis, including 29–36 tons of domestic production and 65 tons of foreign manufacturers. In 2016–2019, the hospital used a smaller number of antidepressants TH – 78–79 TH, including 27–29 TH of domestic production and 52–49 TH – imported. The number of trade names of antidepressants in outpatient consumption is 16–22% higher than the number of trade names in hospital consumption, which may be due to lower government procurement of drugs in this group. It was found that outpatient consumption of antidepressants in the period 2015–2019 increased 2.22 times – from 1.08 DID in 2015 to 2.40 DID in 2019. Consumption in hospitals was much lower and ranged from 0.20 DID in 2016. Up to 0.19 DID in 2019 (With a peak of 0.24 DID in 2017). The increase in the use of outpatient antidepressants was gradual, without abrupt changes. Most INN antidepressants, with the exception of N06AX20 Various drugs and the herb St. John's wort N06AX25, have been included in modern medical and technological documents: the State State form of drugs (8–11 issues) and the List of domestic and foreign drugs that can be purchased by health facilities, which are fully or partially funded from the state and local budgets (2015–2017), which indicates their proven clinical efficacy and safety.

Sign in / Sign up

Export Citation Format

Share Document